IGI Logo

Senores Pharmaceuticals is currently trading at Rs. 546.85, up by 12.35 points or 2.31% from its previous closing of Rs. 534.50 on the BSE.

The scrip opened at Rs. 539.00 and has touched a high and low of Rs. 564.80 and Rs. 539.00 respectively. So far 110952 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 644.40 on 06-Feb-2025 and a 52 week low of Rs. 440.00 on 13-Jan-2025.

Last one week high and low of the scrip stood at Rs. 564.80 and Rs. 492.40 respectively. The current market cap of the company is Rs. 2540.78 crore.

The promoters holding in the company stood at 45.76%, while Institutions and Non-Institutions held 15.74% and 38.48% respectively.

Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed an agreement to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for ‘Roflumilast’ 250 mcg and 500 mcg tablets from Breckenridge Pharmaceutical, Inc., a U.S. subsidiary of Towa International that markets, distributes, and sells generic pharmaceuticals in the United States.  

Roflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis and a history of exacerbations. The market size of Roflumilast in the USA was around $32 million (MAT June 2024) as per IQVIA and around $46 million (MAT September 2024) as per the specialty data aggregator Symphony. The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by SPL. This is in line with the objects of the IPO stated in the Red Herring Prospectus. 

Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms.